Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Pregabalin Extended Release
Generic Name
Pregabalin
Active Ingredient
PregabalinCategory
Other
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Pregabalin Extended Release, you must consult a qualified healthcare professional.
| 50228-463 |
Detailed information about Pregabalin Extended Release
Pregabalin is a potent gabapentinoid medication used to treat neuropathic pain, fibromyalgia, and as an adjunctive therapy for partial-onset seizures. It works by modulating calcium channels in the central nervous system to reduce excitatory neurotransmitter release.
The dosage of Pregabalin must be individualized based on the condition being treated and the patient's response. Clinical guidelines typically suggest starting at a low dose and gradually increasing (titrating) to the effective dose to minimize side effects like dizziness and sleepiness.
Pregabalin is FDA-approved as adjunctive therapy for partial-onset seizures in pediatric patients as young as 1 month of age. Dosing in children is strictly weight-based:
Pregabalin has not been established as safe or effective for fibromyalgia or neuropathic pain in pediatric patients under the age of 18.
Because Pregabalin is cleared by the kidneys, dosage must be reduced in patients with a Creatinine Clearance (CrCl) of less than 60 mL/min. For example, patients with severe renal impairment (CrCl 15-30 mL/min) may only receive a starting dose of 25-50 mg once daily. Your healthcare provider will use blood tests to calculate your kidney function before prescribing.
No dosage adjustment is typically required for patients with liver disease, as Pregabalin does not undergo significant hepatic metabolism.
Older adults are more likely to have decreased renal function and increased sensitivity to the sedative effects of Pregabalin. Healthcare providers usually start elderly patients at the lowest possible dose and monitor closely for falls or confusion.
Pregabalin should be taken exactly as prescribed. It can be taken with or without food. If you are using the oral solution, use a calibrated measuring device (not a household spoon) to ensure the dose is accurate. Extended-release tablets must be swallowed whole; do not crush, chew, or break them, as this can release the entire dose at once, increasing the risk of toxicity. For the best results, try to take your doses at the same time each day to maintain steady levels in your bloodstream. Store the medication at room temperature, away from moisture and heat, and keep it in a secure location to prevent unauthorized use.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at once to make up for a missed one. Frequent missed doses can reduce the effectiveness of the treatment and may increase the risk of breakthrough seizures in patients with epilepsy.
Signs of a Pregabalin overdose may include extreme sleepiness, confusion, agitation, restlessness, and in severe cases, seizures or coma. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining the airway and monitoring cardiac function. In extreme cases, hemodialysis may be used to remove Pregabalin from the blood.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can cause withdrawal symptoms.
Pregabalin is generally well-tolerated, but because it affects the central nervous system, certain side effects are very common, especially during the first few weeks of treatment.
Pregabalin is a potent medication that requires careful medical supervision. It is classified as a Schedule V controlled substance because it can produce feelings of relaxation and euphoria, which may lead to misuse or addiction. Patients with a history of substance abuse (alcohol or drugs) should be monitored closely while taking this medication. It is also vital to understand that Pregabalin should never be shared with others, as the dose required for one person could be dangerous for another.
There are currently no FDA black box warnings for Pregabalin. However, the FDA requires all anticonvulsant medications to carry a general warning regarding the increased risk of suicidal thoughts and behaviors. Patients, caregivers, and families should be alert for the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, ideation, or behavior about self-harm.
There have been reports of angioedema (swelling of the deeper layers of the skin) in patients during initial and chronic treatment. This can occur even without a history of similar reactions. If swelling of the face, tongue, or throat occurs, the medication must be discontinued immediately, and emergency care sought.
While there are few absolute contraindications based solely on drug-drug interactions (due to Pregabalin's lack of hepatic metabolism), it should not be used in combination with other drugs that the patient has a known severe allergy to. Additionally, using Pregabalin with other gabapentinoids (like Gabapentin) is generally avoided as it increases the risk of side effects without providing significant additional therapeutic benefit.
Combining Pregabalin with opioids (such as oxycodone, hydrocodone, or morphine) is highly dangerous. This combination significantly increases the risk of severe respiratory depression, profound sedation, and death. If these must be used together, the lowest effective doses of both should be used, and the patient must be monitored constantly for breathing difficulties.
Drugs like lorazepam (Ativan), diazepam (Valium), or alprazolam (Xanax) can synergistically increase the sedative effects of Pregabalin. This can lead to impaired motor coordination and severe cognitive impairment.
There are specific circumstances where Pregabalin must NEVER be used:
Pregabalin is classified by the FDA as Pregnancy Category C (under the older system). This means that animal studies have shown adverse effects on the fetus (such as structural abnormalities and developmental toxicity), but there are no adequate, well-controlled studies in humans. Data from the North American Antiepileptic Drug (NAAED) Pregnancy Registry has suggested a potential increase in the risk of major birth defects, although the data is not yet definitive. Pregabalin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Women of childbearing age should discuss effective contraception with their doctor while taking this medication.
Pregabalin is known to be excreted in human breast milk. Based on studies, the 'relative infant dose' is estimated to be around 7% of the mother's weight-adjusted dose. While this is relatively low, the long-term effects of Pregabalin exposure on a developing infant's nervous system are unknown. Breastfeeding is generally not recommended while taking Pregabalin, or if it is continued, the infant should be closely monitored for drowsiness, poor feeding, and appropriate developmental milestones.
Pregabalin's primary molecular target is the α2-δ (alpha-2-delta) protein, an auxiliary subunit of voltage-gated calcium channels found in the brain and spinal cord. By binding to this subunit, Pregabalin reduces the calcium-dependent release of several excitatory neurotransmitters. Specifically, it modulates the release of glutamate (the brain's primary excitatory signal), norepinephrine, and substance P. This modulation occurs primarily in 'over-excited' neurons, which explains why the drug can reduce pathological pain and seizure activity without significantly disrupting normal nerve communication. It does not interact with sodium channels, opiate receptors, or cyclooxygenase enzymes, and it does not alter GABA levels or binding directly.
The pharmacodynamics of Pregabalin are characterized by a dose-dependent reduction in pain and seizure frequency. The onset of action for neuropathic pain can be as early as one week, though full therapeutic benefits may take several weeks to manifest. In fibromyalgia, improvements in sleep and pain are often reported within the first 1-2 weeks. Tolerance to the therapeutic effects is generally low, meaning the drug remains effective over long periods, though physical dependence can occur.
Common questions about Pregabalin Extended Release
Pregabalin is primarily used to manage chronic pain conditions caused by nerve damage, such as diabetic peripheral neuropathy and postherpetic neuralgia (pain after shingles). It is also FDA-approved to treat fibromyalgia, a condition characterized by widespread pain and fatigue. Additionally, it is used as an 'add-on' or adjunctive therapy for adults and children with partial-onset seizures. Some doctors may also prescribe it off-label for conditions like generalized anxiety disorder or restless legs syndrome. It works by calming overactive nerves in the central nervous system.
The most frequent side effects reported by patients taking Pregabalin include dizziness and significant sleepiness (somnolence). Many people also experience dry mouth, blurred vision, and weight gain, which is often linked to an increased appetite or fluid retention (edema). Difficulty with concentration and memory, sometimes called 'brain fog,' is also common. Most of these side effects are dose-dependent and may improve as your body adjusts to the medication. However, if they become bothersome or severe, you should contact your healthcare provider.
No, you should avoid drinking alcohol while taking Pregabalin. Both alcohol and Pregabalin are central nervous system depressants, meaning they slow down brain activity. When taken together, they can cause extreme drowsiness, dangerously slow breathing, and impaired motor coordination, which increases the risk of falls and accidents. In severe cases, this combination can lead to a life-threatening overdose. Always consult your doctor before consuming any amount of alcohol if you are on this medication.
Pregabalin is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. Animal studies have shown that high doses can lead to structural birth defects and developmental issues. Human data is limited, but some registries suggest a possible increase in the risk of major malformations. If you are pregnant or planning to become pregnant, it is essential to have a detailed discussion with your doctor. They may suggest alternative treatments or monitor your pregnancy more closely if Pregabalin is necessary.
The time it takes for Pregabalin to work varies depending on the condition being treated and the individual patient. For neuropathic pain or fibromyalgia, some patients notice an improvement in their symptoms within the first week of treatment. However, for others, it may take two to four weeks of consistent dosing to reach the full therapeutic effect. It is important to continue taking the medication as prescribed, even if you do not feel immediate relief. Your doctor will likely start you on a low dose and gradually increase it to find the most effective level for you.
You should never stop taking Pregabalin suddenly without consulting your doctor. Abruptly stopping the medication can cause withdrawal symptoms, including insomnia, nausea, headache, anxiety, and diarrhea. For patients taking the drug for epilepsy, stopping suddenly can trigger a rapid series of seizures (status epilepticus), which is a medical emergency. To safely discontinue Pregabalin, your healthcare provider will provide a tapering schedule, usually reducing the dose gradually over at least one week to allow your nervous system to adjust.
If you miss a dose of Pregabalin, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time to make up for the one you missed, as this increases the risk of side effects and toxicity. If you find yourself frequently forgetting doses, consider using a pill organizer or setting an alarm on your phone. Consistency is key to managing chronic pain and preventing seizures.
Yes, weight gain is a well-documented side effect of Pregabalin. In clinical trials, a significant percentage of patients experienced weight increases of 7% or more from their baseline. This gain is often a result of both an increase in appetite and peripheral edema (fluid retention in the legs and hands). While some of this weight gain may be manageable through diet and exercise, it is important to monitor your weight regularly. If you notice rapid weight gain or significant swelling, you should discuss these changes with your healthcare provider.
Pregabalin can interact with several other medications, particularly those that also affect the central nervous system. It is especially dangerous to take Pregabalin with opioids, benzodiazepines, or other sedatives, as this combination can lead to severe respiratory depression. There is also an increased risk of swelling (angioedema) when taken with ACE inhibitors, and increased fluid retention when taken with certain diabetes medications like pioglitazone. Always provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are using.
Yes, Pregabalin is widely available as a generic medication. The generic version was first approved by the FDA in 2019 and is chemically identical to the brand-name version, Lyrica. Generic Pregabalin is typically much more affordable than the brand-name drug and is covered by most insurance plans. Both the capsules and the oral solution are available in generic forms. When switching from brand-name to generic, or vice-versa, the effectiveness and side effects should remain the same, but you should always confirm the change with your pharmacist.
Other drugs with the same active ingredient (Pregabalin)
These effects occur in a smaller percentage of patients but are still well-documented in clinical trials:
While rare, some side effects of Pregabalin are life-threatening. Seek emergency care if you experience:
> Warning: Stop taking Pregabalin and call your doctor immediately if you experience any of these serious symptoms.
With prolonged use, some patients may experience persistent weight gain, which can increase the risk of developing type 2 diabetes or cardiovascular issues. There is also a risk of physical and psychological dependence. Long-term cognitive effects are still being studied, but some patients report ongoing issues with short-term memory. Additionally, because Pregabalin is cleared renally, long-term use in patients with borderline kidney function requires regular monitoring to prevent drug accumulation and toxicity.
Currently, Pregabalin does not carry a formal FDA 'Black Box Warning.' However, in 2019, the FDA issued a significant Safety Communication warning about the risk of serious breathing difficulties in patients using Pregabalin who have respiratory risk factors. This includes patients using opioid pain medications, those with Chronic Obstructive Pulmonary Disease (COPD), or the elderly. While not a black box, this is considered a critical safety alert that healthcare providers must weigh when prescribing the drug.
Report any unusual symptoms to your healthcare provider promptly. Early intervention can often prevent side effects from becoming severe.
In 2019, the FDA strengthened warnings regarding respiratory depression. When Pregabalin is taken with other drugs that slow the central nervous system (like opioids or benzodiazepines) or in patients with underlying lung disease, the risk of life-threatening breathing problems increases significantly. Symptoms include extreme sleepiness and very slow breathing.
Pregabalin can cause fluid retention (edema). This is particularly dangerous for patients with New York Heart Association (NYHA) Class III or IV heart failure. Fluid retention can worsen heart failure symptoms, such as shortness of breath and swelling in the extremities.
Clinical trials of various anticonvulsants, including Pregabalin, showed a small increase in the risk of suicidal thinking and behavior (0.43% in the drug group vs. 0.24% in the placebo group). This risk can appear as early as one week after starting the medication.
Patients taking Pregabalin should undergo regular clinical evaluations. Key monitoring parameters include:
Pregabalin may cause significant dizziness, somnolence, and blurred vision. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they know how the medication affects them. The sedative effects are most pronounced during the first few weeks of therapy or following a dose increase.
Alcohol should be strictly avoided while taking Pregabalin. Alcohol significantly enhances the CNS-depressant effects of the drug, leading to extreme drowsiness, respiratory distress, and an increased risk of accidental injury or overdose.
Pregabalin must never be stopped abruptly. Sudden discontinuation can lead to a withdrawal syndrome characterized by insomnia, nausea, headache, anxiety, hyperhidrosis (excessive sweating), and diarrhea. In patients with epilepsy, stopping the drug suddenly can trigger status epilepticus (prolonged, life-threatening seizures). Healthcare providers will typically taper the dose gradually over at least one week.
> Important: Discuss all your medical conditions, especially kidney disease, heart problems, and history of depression or addiction, with your healthcare provider before starting Pregabalin.
Drugs like pioglitazone or rosiglitazone are known to cause fluid retention. When combined with Pregabalin, the risk of peripheral edema and potentially worsening heart failure is increased. Weight and swelling should be monitored closely in diabetic patients using this combination.
Pregabalin does not have major interactions with specific foods like grapefruit or dairy. However, taking the medication with a high-fat meal can delay the time it takes for the drug to reach peak levels in the blood. While this doesn't change the overall effectiveness, it might delay the onset of pain relief. As previously mentioned, alcohol is the most critical 'substance' interaction to avoid.
Supplements with sedative properties, such as Valerian root, Kava, St. John's Wort, or Melatonin, can increase the drowsiness caused by Pregabalin. Using these together can make it unsafe to drive or perform daily tasks.
While specifically noted for its 'cousin' Gabapentin, some clinicians suggest spacing Pregabalin doses away from antacids to ensure optimal absorption, although the interaction is significantly less pronounced with Pregabalin.
Pregabalin is not known to interfere with most common laboratory tests. However, it can occasionally cause a decrease in platelet counts or an increase in blood creatine kinase levels. If you are undergoing a drug screen, Pregabalin does not typically cause a false positive for opioids or benzodiazepines, but specialized tests can detect its presence.
For each major interaction, the mechanism is usually pharmacodynamic (meaning the drugs have additive effects on the body) rather than pharmacokinetic (meaning they change each other's blood levels). This is because Pregabalin is not processed by the liver's CYP450 system.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and sleep aids.
There is no documented direct cross-sensitivity between Pregabalin and other classes of anticonvulsants (like carbamazepine or valproate). However, patients who have had a severe reaction to Gabapentin (Neurontin) should be approached with caution. Although they are different molecules, they share a similar chemical backbone and mechanism of action, and anecdotal evidence suggests some patients may react poorly to both.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies or chronic health conditions, before prescribing Pregabalin to ensure it is the safest option for you.
Patients aged 65 and older are at a higher risk for several complications with Pregabalin. First, renal function naturally declines with age, meaning the 'standard' dose may be too high for an elderly patient, leading to drug accumulation. Second, the CNS effects—dizziness and ataxia—significantly increase the risk of falls and hip fractures in the elderly. Healthcare providers typically 'start low and go slow' with dosing in this population and monitor kidney function frequently.
As the kidneys are the primary route of elimination for Pregabalin, renal impairment is the most significant factor in drug toxicity. Doses must be adjusted based on the calculated Creatinine Clearance (CrCl). For patients on hemodialysis, an additional supplemental dose is usually required after each dialysis session, as the procedure effectively removes the drug from the blood.
Since Pregabalin is not significantly metabolized by the liver, no dosage adjustment is required for patients with hepatic impairment (Child-Pugh Class A, B, or C). However, these patients often have co-occurring renal issues or are on multiple other medications, so general caution is still advised.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have any history of kidney disease.
|---|---|
| Bioavailability | ≥90% (Dose-independent) |
| Protein Binding | 0% (Negligible) |
| Half-life | ~6.3 hours (Normal renal function) |
| Tmax | ~1.0 hour (Fasting); ~3.0 hours (With food) |
| Metabolism | Negligible (<2% in urine as metabolites) |
| Excretion | Renal 98% (Unchanged drug) |
Pregabalin is chemically described as (S)-3-(aminomethyl)-5-methylhexanoic acid. It has a molecular formula of C8H17NO2 and a molecular weight of 159.23 g/mol. It is a white to off-white crystalline solid and is highly soluble in water and both basic and acidic aqueous solutions. Its structure is a structural analog of the neurotransmitter GABA, but it is modified with a lipophilic (fat-soluble) tail that allows it to cross the blood-brain barrier effectively.
Pregabalin belongs to the Gabapentinoid class of medications. It is specifically an alpha2-delta ligand. While it is grouped with anticonvulsants, its primary clinical use today is as a specialized analgesic for neuropathic pain. It is often compared to Gabapentin (Neurontin), but Pregabalin has higher potency, faster absorption, and more predictable pharmacokinetics.